Ischemix, Inc. Completes Successful Phase 1 Trial of Novel Compound to Treat Traumatic Brain Injury

CMX-2043, a novel, proprietary cytoprotective drug candidate, demonstrated excellent safety and tolerability in a Phase 1 single ascending and multiple ascending dose (SAD-MAD) clinical trial. CMX-2043 has previously demonstrated safety and efficacy in extensive preclinical pharmacology, toxicology and TBI translati...

Related Keywords

Canada ,Montreal ,Quebec ,David Dewahl ,Davida Dewahl Jr ,Ischemix Inc ,Altasciences Company Inc ,Health Affairs ,Us Army Medical Research ,Department Of Defense Contact Information ,Technology Enterprise Consortium Under Award No ,Department Of Defense ,Development Command ,Casualty Care Research Program ,Neurotrauma At Combat Casualty Care Research Program ,Technology Enterprise Consortium ,Technology International ,Principal Investigator ,Chief Medical Officer ,Medical Research ,Combat Casualty Care Research Program ,Medical Technology Enterprise Consortium ,Disease Control ,Combat Casualty Care Research ,Traumatic Brain Injury Portfolio ,Multi Domain Operations ,Advanced Technology ,Assistant Secretary ,Defense Contact Information ,Completes Successful Phase ,Novel Compound ,Treat Traumatic Brain Injury ,